Background
Type 2 diabetes, T2D, CKD, chronic kidney disease, cardiorenal diseases, T2D [, MR
TYPE 2 DIABETES, METABOLIC SYNDROMES, CARDIORENAL DISEASE, END-STAGE RENAL DISEASE, EVENTS
Type 2 diabetes (T2D) is a major cause of chronic kidney disease (CKD) and end-stage renal disease, which pose significant economic and medical burden on worldwide health care [Accumulated evidence suggests that a high plasma aldosterone concentration and mineralocorticoid receptor (MR) overactivation play a pathophysiological role in metabolic syndromes and several cardiorenal diseases via pro-inflammatory and pro-fibrotic signaling-mediated injuries in the tissues and organs [Finerenone is a novel nonsteroidal MRA that has a greater MR selectivity and affinity than steroidal MRAs [Previous data have supported the notion that high vascular stiffness is closely associated with the development of CKD and the risk of cardiovascular events in various populations, including patients with T2D [